FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015362823> ?p ?o ?g. }

• W2015362823 endingPage "211" @default.
• W2015362823 startingPage "201" @default.
• W2015362823 abstract "There has been much research linking elevated resting heart rate to cardiovascular morbidity and mortality. Based on these findings, a lower resting heart rate would be of theoretical benefit in patients with cardiovascular disease. From a pathophysiologic perspective, a lower resting heart rate would be of particular benefit in patients with ischemic heart disease and/or heart failure. Although β-blockers and nondihydropyridine calcium channel blockers are effective at lowering heart rate, they have many other pharmacologic effects that may not be desirable in some patients, such as negative inotropy. Ivabradine is a drug designed to lower heart rate without any other demonstrable pharmacologic effects; in other words, a pure heart rate-lowering drug. It functions by blocking the hyperpolarization-activated cyclic nucleotide gated channels (f-channels) specific for the sinoatrial node and disrupting If ion current flow. This effectively prolongs diastolic depolarization and slows firing in the sinoatrial node, which lowers heart rate. The effects of ivabradine are most pronounced at higher heart rates (use-dependence), which is important in minimizing the development of symptomatic bradycardia. Clinical trials have demonstrated ivabradine to be an effective antianginal drug both alone and in combination with β-blocker therapy, although it has not been shown to produce a demonstrable effect on reducing major adverse cardiovascular events. In patients with heart failure, ivabradine has demonstrated many hemodynamic benefits, but its effect on clinical outcomes have been mixed and dependent on baseline heart rate, ie, the drug may be of benefit with higher baseline heart rates, but detrimental with low baseline heart rates. The adverse effects of ivabradine are not uncommon, but are rarely severe and include visual disturbances, bradycardia, and atrial fibrillation. Although ivabradine is a very interesting new agent, its variable benefits in large-scale clinical trials leave its exact place in therapy still somewhat nebulous. Unanswered questions include which patient populations would benefit most from this drug, and which concomitant medications would produce the best clinical outcomes when used with ivabradine." @default.
• W2015362823 created "2016-06-24" @default.
• W2015362823 creator A5075407150 @default.
• W2015362823 creator A5083284876 @default.
• W2015362823 creator A5089032624 @default.
• W2015362823 date "2015-07-01" @default.
• W2015362823 modified "2023-09-24" @default.
• W2015362823 title "Ivabradine" @default.
• W2015362823 cites W123965450 @default.
• W2015362823 cites W1524672920 @default.
• W2015362823 cites W1567648906 @default.
• W2015362823 cites W1884696473 @default.
• W2015362823 cites W1966637711 @default.
• W2015362823 cites W1968096578 @default.
• W2015362823 cites W1977529073 @default.
• W2015362823 cites W1979947635 @default.
• W2015362823 cites W1985299539 @default.
• W2015362823 cites W1986954788 @default.
• W2015362823 cites W1989036742 @default.
• W2015362823 cites W1999660133 @default.
• W2015362823 cites W2001966526 @default.
• W2015362823 cites W2014005986 @default.
• W2015362823 cites W2018503358 @default.
• W2015362823 cites W2019468355 @default.
• W2015362823 cites W2022608906 @default.
• W2015362823 cites W2034047310 @default.
• W2015362823 cites W2035327843 @default.
• W2015362823 cites W2046746746 @default.
• W2015362823 cites W2047445883 @default.
• W2015362823 cites W2053138185 @default.
• W2015362823 cites W2056665255 @default.
• W2015362823 cites W2059790969 @default.
• W2015362823 cites W2063990451 @default.
• W2015362823 cites W2071987892 @default.
• W2015362823 cites W2121210240 @default.
• W2015362823 cites W2125442653 @default.
• W2015362823 cites W2129413040 @default.
• W2015362823 cites W2136605213 @default.
• W2015362823 cites W2136642260 @default.
• W2015362823 cites W2137688499 @default.
• W2015362823 cites W2144207672 @default.
• W2015362823 cites W2145270758 @default.
• W2015362823 cites W2147095760 @default.
• W2015362823 cites W2153622558 @default.
• W2015362823 cites W2154143064 @default.
• W2015362823 cites W2155808437 @default.
• W2015362823 cites W2159461724 @default.
• W2015362823 cites W2164145340 @default.
• W2015362823 cites W2164912716 @default.
• W2015362823 cites W2170675714 @default.
• W2015362823 cites W2327160268 @default.
• W2015362823 cites W2345335936 @default.
• W2015362823 cites W3183915260 @default.
• W2015362823 cites W4319308498 @default.
• W2015362823 doi "https://doi.org/10.1097/crd.0000000000000070" @default.
• W2015362823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25839989" @default.
• W2015362823 hasPublicationYear "2015" @default.
• W2015362823 type Work @default.
• W2015362823 sameAs 2015362823 @default.
• W2015362823 citedByCount "14" @default.
• W2015362823 countsByYear W20153628232015 @default.
• W2015362823 countsByYear W20153628232016 @default.
• W2015362823 countsByYear W20153628232017 @default.
• W2015362823 countsByYear W20153628232018 @default.
• W2015362823 countsByYear W20153628232019 @default.
• W2015362823 countsByYear W20153628232020 @default.
• W2015362823 countsByYear W20153628232021 @default.
• W2015362823 countsByYear W20153628232022 @default.
• W2015362823 crossrefType "journal-article" @default.
• W2015362823 hasAuthorship W2015362823A5075407150 @default.
• W2015362823 hasAuthorship W2015362823A5083284876 @default.
• W2015362823 hasAuthorship W2015362823A5089032624 @default.
• W2015362823 hasConcept C126322002 @default.
• W2015362823 hasConcept C164705383 @default.
• W2015362823 hasConcept C2777495988 @default.
• W2015362823 hasConcept C2777953023 @default.
• W2015362823 hasConcept C2778198053 @default.
• W2015362823 hasConcept C2778542873 @default.
• W2015362823 hasConcept C2779167562 @default.
• W2015362823 hasConcept C2780074459 @default.
• W2015362823 hasConcept C71924100 @default.
• W2015362823 hasConcept C84393581 @default.
• W2015362823 hasConceptScore W2015362823C126322002 @default.
• W2015362823 hasConceptScore W2015362823C164705383 @default.
• W2015362823 hasConceptScore W2015362823C2777495988 @default.
• W2015362823 hasConceptScore W2015362823C2777953023 @default.
• W2015362823 hasConceptScore W2015362823C2778198053 @default.
• W2015362823 hasConceptScore W2015362823C2778542873 @default.
• W2015362823 hasConceptScore W2015362823C2779167562 @default.
• W2015362823 hasConceptScore W2015362823C2780074459 @default.
• W2015362823 hasConceptScore W2015362823C71924100 @default.
• W2015362823 hasConceptScore W2015362823C84393581 @default.
• W2015362823 hasIssue "4" @default.
• W2015362823 hasLocation W20153628231 @default.
• W2015362823 hasLocation W20153628232 @default.
• W2015362823 hasOpenAccess W2015362823 @default.
• W2015362823 hasPrimaryLocation W20153628231 @default.
• W2015362823 hasRelatedWork W1736343608 @default.

• next